Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 8/20 | 0.62 |
| ▸ | ADRB1 | P08588 | 8/20 | 0.62 |
| ▸ | ADRA1D | P25100 | 8/20 | 0.62 |
| ▸ | ADRB3 | P13945 | 8/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 7/20 | 0.62 |
| ▸ | ADRA1B | P35368 | 7/20 | 0.62 |
| ▸ | BLM | P54132 | 5/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.62 |
| ▸ | HPGD | P15428 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | RECQL | P46063 | 3/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.62 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.62 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.62 |
| ▸ | APEX1 | P27695 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30883921 | 1.00 | ADRB2 (0.62) | ADRB2ADRB1ADRA1DADRB3ADRA1A | |
| SCHEMBL9135589 | 1.00 | ADRB2 (0.62) | ADRB2ADRB1ADRA1DADRB3ADRA1A | |
| Hydrochloric Acid SCHEMBL9135207 | 0.98 | ADRB2 (0.61) | ADRB2ADRB1ADRA1DADRB3ADRA1A | |
| SCHEMBL29217760 | 0.86 | KDM4E (0.64) | ADRB2ADRB1ADRA1DADRB3ADRA1A | |
| SCHEMBL30883926 | 0.85 | ADRB2 (0.54) | ADRB2ADRB1ADRA1DADRB3ADRA1A | |
| SCHEMBL30883924 | 0.85 | ADRB2 (0.54) | ADRB2ADRB1ADRA1DADRB3ADRA1A | |
| SCHEMBL30883923 | 0.85 | ADRB2 (0.51) | ADRB2ADRB1ADRA1DADRB3ADRA1A | |
| SCHEMBL9794851 | 0.85 | ADRB2 (0.51) | ADRB2ADRB1ADRA1DADRB3ADRA1A | |
| SCHEMBL30883922 | 0.85 | ADRB2 (0.51) | ADRB2ADRB1ADRA1DADRB3ADRA1A | |
| SCHEMBL29217695 | 0.85 | ADRB2 (0.54) | ADRB2ADRB1ADRA1DADRB3ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022716-B2 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH (US) | 2006-04-04 | — | — | US | disclosed |
| US-20030144326-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH | 2003-07-31 | — | — | US | disclosed |
| US-20030143701-A1 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. | 2003-07-31 | — | — | US | disclosed |
| EP-0924194-B1 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEM (JP) | 2003-05-14 | — | — | EP | disclosed |
| EP-1301482-A1 | CYCLIC AMINE PHENYL BETA-3 ADRENERGIC RECEPTOR AGONISTS | Wyeth (US) | 2003-04-16 | — | — | EP | disclosed |
| US-6528686-B1 | Reacting primary amine and ketone functionalized derivatives; catalytically reducing | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2003-03-04 | — | — | US | disclosed |
| US-6525202-B2 | E.g., substituted (4-amino-5-hydroxyphenyl)-oxy-)piperidinyl thiazolidin-2,4-dione; antidiabetic agents; atherosclerosis, gastrointestinal, metabolic disorders, glaucoma, neurogenetic inflammation, ocular hypertension and frequent urination | WYETH | 2003-02-25 | — | — | US | disclosed |
| EP-0924193-B1 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEM (JP) | 2003-02-19 | — | — | EP | disclosed |
| EP-0939134-B1 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEM (JP) | 2002-09-11 | — | — | EP | disclosed |
| US-20020028835-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH | 2002-03-07 | — | — | US | disclosed |
| WO-2002006232-A1 | CYCLIC AMINE PHENYL BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
| US-6114582-A | DECYCLIZATION TO FORM A CHEMICAL INTERMEDIATE FOR PRODUCING AN ANTI-OBESITY AGENT AND ANTIDIABETIC AGENT | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2000-09-05 | — | — | US | disclosed |
| EP-0654534-B1 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEM (JP) | 2000-03-01 | — | — | EP | disclosed |
| EP-0939134-A1 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1999-09-01 | — | — | EP | disclosed |
| EP-0924193-A1 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1999-06-23 | — | — | EP | disclosed |
| EP-0924194-A2 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1999-06-23 | — | — | EP | disclosed |
| US-5811293-A | CULTURE PRODUCT AS CHEMICAL INTERMEDIATE FOR ANTI-OBESITY AGENT | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1998-09-22 | — | — | US | disclosed |
| US-5629200-A | MICROORGANISM | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1997-05-13 | — | — | US | disclosed |
| EP-0654534-A2 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144326-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | ADRB2 3/4885ADRB1 1/4885ADRA1D 6/4885 |
| US-20020028835-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | ADRB2 3/4885ADRB1 1/4885ADRA1D 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.